N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
CAS: 33288-71-0
Ref. 3D-FA150607
1g | 991.00 € | ||
50mg | 136.00 € | ||
100mg | 190.00 € | ||
250mg | 396.00 € | ||
500mg | 687.00 € |
Product Information
- 2-pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
- 4-[2-(5-Methyl-2-pyrazine carboxamido)ethyl]benzene sulfonamide
- 4-[2-(5-Methylpyrazine-2-carboxamido)ethyl]benzenesulfonamide
- 4-[2-(5-Methylpyrazinyl-2-carboxamido)ethyl]benzenesulfonamide
- 5-Methyl-N-[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide
- N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-5-methyl-2-pyrazinecarboxamide
- Pyrazinecarboxamide, 5-methyl-N-(p-sulfamoylphenethyl)-
- Pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
Fluoxetine is a potent inhibitor of the enzyme cytochrome P450 (CYP) 2C19. The inhibition of CYP2C19 by fluoxetine may lead to an increase in the plasma concentration of other drugs that are metabolized by this enzyme, such as glipizide and hydroxycyclohexyl. Fluoxetine inhibits human uric acid secretion and increases plasma concentrations of uric acid. This drug also inhibits human erythrocyte dihydropyrimidine dehydrogenase, leading to increased blood levels of pyrimidines, especially cytotoxic ones like 6-fluoro-3-indoxyl-beta-D-galactopyranoside. Fluoxetine has been shown to have a protective effect against acetaminophen toxicity in rats because it enhances the conversion of acetaminophen to its less toxic metabolite N-acetylcysteine.
Chemical properties
Technical inquiry about: 3D-FA150607 N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.